A Food and Drug Administration advisory panel approved of the broad distribution of the Pfizer COVID-19 vaccine, the Wall Street Journal reports.
After a day-long hearing on the efficacy of the vaccine produced by Pfizer Inc. and its partner BioNTech SE, the FDA's Vaccines and Related Biological Products Advisory Committee voted 17-to-4, with one abstention, in favor of the vaccine's approval, according to the WSJ.
The FDA panel reportedly decided that the benefits of the vaccine outweighed the associated risks for people older than 16 years of age.
The disease is now "essentially out of control," Kathrin Jansen, Pfizer’s head of vaccine research and development, told the panel.
"Vaccine introduction is an urgent need," she continued.
There are expected to be enough doses of the vaccine to immunize 20 million high risk individuals by the end of the year, according to Health and Human Services Secretary Alex Azar.
The FDA will reportedly allow emergency authorizations for use starting Friday.
Powered by StructureCMS™ Comments
Join and support independent free thinkers!
We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.
Remind me next month
To find out what personal data we collect and how we use it, please visit our Privacy Policy
Comments